Claims

15

20

1. A compound of formula (1)

- wherein R_1 is 2-indanyl, R_2 is 1-methylpropyl, R_3 is 2-methyl-1,3-oxazol-4-yl and R_4 and R_5 together with the nitrogen atom to which they are attached represents morpholino.
- 2. (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione.
 - 3. (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1R)-1-methylpropyl]-2,5-piperazinedione.
 - 4. A pharmaceutical composition comprising a compound of formula (1) as claimed in 1 together with one or more pharmaceutically acceptable carriers.
 - 5. The use of compound of formula (1) as defined in claim 1 for the manufacture of a medicament for antagonising the effects of oxytocin on the oxytocin receptor.
- 25 6. A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a

WO 2005/000840 PCT/EP2004/006814

mammal in need thereof of an effective amount of a compound of the formula (I)

- 7. A process for A the preparation of compounds of formula (I) which5 comprises:
 - (a) reacting a compound of formula (II)

wherein R_1 , R_2 and R_3 have the meanings defined in claim 1 or a mixed anhydride thereof, with the amine NHR₄R₅ wherein R₄ and R₅ have the meaning defined in formula (I) under the standard condition for preparing amides from a carboxylic acid or a mixed anhydride thereof and an amine.

(b) reacting a compound of formula (III)

15

20

10

wherein R_1 , R_2 and R_3 have the meanings defined in claim 1 and R_6 is 2-hydroxyphenyl with carbonyldiimidazole or thiocarbonyldiimidazole in a suitable solvent and subsequent reaction of the product thus formed with amine NHR₄R₅ wherein R₄ and R₅ have the meaning defined in formula (I).